NOV 06, 2016 03:48 PM PST

Drug for Neglected Disease Activated by Newly Found Enzyme

WRITTEN BY: Carmen Leitch
Neglected diseases are those that affect the world’s poor and are usually common in tropical areas. A new discovery could aid in the treatment of one such disease, Visceral leishmaniasis (VL) which is also known as Kala-azar. Researchers at the University of Dundee in New Zealand, an area of research on neglected diseases, have found a protein that can help improve the efficacy of a drug that was recently identified as a therapeutic for VL.
 

VL, described in the video above, that affects roughly two to four hundred thousand people globally, according to the Centers for Disease Control. It is a parasitic infection that can range from a silent infection, with no symptoms, to more serious cases of fever, weight loss and liver and spleen problems. It primarily affects people in Brazil, India, Nepal, Bangladesh, Ethiopia, South Sudan and Sudan. The current treatments have considerable limitations such as high cost, toxicity, side effects, prolonged administration and drug resistance; there are no vaccines.
 
"There has been considerable interest in developing new compounds to target diseases like leishmaniasis, particularly because the existing drugs are very unsatisfactory and increasingly becoming unusable due to resistance in the parasite," said Professor Alan Fairlamb, Wellcome Principal Research Fellow in the School of Life Sciences at Dundee. He is the senior author of the work, reported in PLOS Pathogens.
 
Fairlamb, in collaboration with Dr. Kevin Read and colleagues have previously shown that one drug used to treat tuberculosis, called delamanid, can potentially also treat VL. Their new work with a team at the Wellcome Trust Sanger Institute in Cambridge, UK, identified a protein that is characterized as a nitroreductase – an enzyme that targets nitrogen compounds, and shows that it can improve the efficacy of delamanid as a VL nitro-drug. An example of a nitroreductase is shown below.
 

 
The researchers term the newly found protein nitroreductase NTR2. The researchers show that it can result in hypersensitivity to bicyclic nitro compounds like delamanid. Another type of nitroreductase, NTR1, activates other types of nitrogen compounds, monocyclic nitro-drugs.
 
"One concern has been that if all nitro-drugs are activated by NTR1, then loss of this protein would lead to widespread drug resistance to both unicyclic drugs (fexinidazole) and bicyclic drugs (delamanid). We have discovered this new protein, NTR2 that specifically activates drugs like delamanid but not fexinidazole," explained Fairlamb
 
"This knowledge is extremely important in that it allows us to design better drugs activated by NTR2 and to suggest drug combinations that will reduce the risk of emergence of drug resistance through loss of either NTR1 or NTR2 activity. It also provides a potential diagnostic marker for resistance should it arise," said Fairlamb.
 
One drug identified by the researchers, fexinidazole, is undergoing phase II clinical trials in Africa as part of the Drugs for Neglected Diseases initiative. Delamanid has been considered for immediate trials in VL patients.
 
"Further work is now needed to find the most appropriate partner drugs to be used to increase efficacy and decrease toxicity in patients, to minimize the risk of drug resistance emerging and in designing second generation drugs.” Fairlamb concluded.

If you would like to know more about neglected disease of the world, watch the following video.
 

 
Sources: AAAS/Eurekalert! via Dundee University, PLOS Pathogens
 
About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
SEP 27, 2018
Microbiology
SEP 27, 2018
How Bacterial Cells Take out the Trash
Some types of bacteria create tiny versions of themselves that cannot reproduce - miniature spheres lacking chromosomal DNA that are known as minicells....
SEP 27, 2018
Genetics & Genomics
SEP 27, 2018
Learning What Causes Algae Blooms to Turn Toxic
According to the EPA, algal blooms threaten every state and in our changing climate, they may be more common....
SEP 27, 2018
Videos
SEP 27, 2018
Finding Beauty in Parasitic Replication
The toxoplasma parasite uses mammalian cells to replicate, as seen in this incredible image....
OCT 02, 2018
Cell & Molecular Biology
OCT 02, 2018
Approved Drug may Slow the Progression of Alzheimer's
For many, Alzheimer's disease is just a fact of old age; around 50 percent of people that live to age 85 will get the disorder....
OCT 06, 2018
Videos
OCT 06, 2018
Explore a Human Cell with an Interactive Website
The Allen Institute is aiming to enhance our understanding of how human cells function....
OCT 07, 2018
Cell & Molecular Biology
OCT 07, 2018
Towards a Deeper Understanding of Heart Development
If we learn how the heart is built, we may learn how to mend a broken one....
Loading Comments...